Nanomaterials 2020 Young Investigator Award MDPI, Nanomaterials Journal	CEDOC researchers stand out in the top 2% of the most cited authors in their field CEDOC researchers Miguel Seabra, principal investigator of Molecular Mechanisms of Disease group, Pedro Póvoa, from Integrated Pathophysiological Mechanisms group, and Winchil Vaz, from Lysosomes in Chronic Human Pathology and Infection group, integrate the group of the most cited scientists worldwide in different disciplines, ranking in the top 2% in their respective fields. João Conde, from Cancer Nanomedicine group, presently working at CEDOC, also integrates this list.	Q&A Spotlight on early-career researchers Nature Communications Biology - “Swallowing the doctor”: an interview with João Conde about the future of nanomedicine
Recent Nanotechnology Applications to Combat the SARS-CoV-2 Pandemic AZO NANO Editorial Feature	RTP News João Conde ganha prémio ERC Um milhão de euros para pesquisa portuguesa de novas terapias do cancro de mama	EXPRESSO News Estudos portugueses sobre fake news e sobre terapia do cancro da mama ganham bolsas milionárias do Conselho Europeu de Investigação
PUBLICO News Cancro da mama e fake news trazem 2,9 milhões de euros de bolsas europeias	IMM News Conselho Europeu de Investigação distingue investigador do IMM	Wellcome Image Awards 2017 MicroRNA scaffold cancer therapy. Credit: João Conde, Nuria Oliva and Natalie Artzi
MIT News September 2016 Gene therapy technique may help prevent cancer metastasis. Gene-regulating RNA molecules could help treat early-stage breast cancer tumors before they spread.	MIT News July 2016 Patch that delivers drug, gene, and light-based therapy to tumor sites shows promising results. In mice, device destroyed colorectal tumors and prevented remission after surgery.	Science Translational Medicine Science Translational Medicine Highlight - Editors' Choice in Cancer - Triple threat to colorectal cancer
Brigham and Women's Hospital Press Releases Triple-Therapy Patch Delivers Local Treatment, Prevents Recurrence in Colon Cancer Model	MIT Webpage Dec 8 2015 RNA triplex scaffolds featured on MIT webpage MicroRNA delivery: Researchers find a new way to deliver microRNAs for breast cancer treatment	Nature Materials Frontpage RNA delivery. João Conde et al. Tissue-adhesive scaffolds made by the conjugation of RNA triple helices to dendrimers lead to ~90% shrinkage of tumours two weeks after implantation in a triple-negative breast cancer mouse model.
MIT News December 2015 MIT researchers developed this hydrogel embedded with triple helix microRNA particles and used it to treat cancer in mice. microRNA nanoparticles can light up green or red when they encounter their target.	MIT News December 2015 A new way to deliver microRNAs for cancer treatment. Scientists exploit gene therapy to shrink tumors in mice with an aggressive form of breast cancer.	Science Translational Medicine Science Translational Medicine Highlight - Editors' Choice in Cancer Nanotechnology - Efficacy by design
BioTechniques News "The Incredible Shrinking Tumor" New technology applies cancer-fighting microRNAs directly to tumors, which could significantly reduce side effects of treatment.	NCI image award 2016 National Cancer Institute Image award: Cancer close up, USA. Credit: João Conde, Nuria Oliva, Natalie Artzi	BWH Clinical & Research News Shrinking Tumors with an RNA Triple-Helix Hydrogel Glue. Researchers at Brigham and Women’s Hospital (BWH) have developed an efficient and effective delivery vehicle for gene therapy, and have used it to shrink tumors by nearly 90 percent in a pre-clinical model of triple-negative breast cancer.
MIT News March 2015 Part II Hydrogel embedded with gold nanoparticles coated with DNA targeting	Nature Reviews Drug Discovery 2015 RESEARCH HIGHLIGHT in Nature Reviews Drug Discovery May 2015 Multifunctional nanodevice reverses drug resistance	Cosmos Magazine March 2015 A gold Trojan nano-horse that fights cancer. Gold nanoparticles designed to kill cancer cells are showing promise.
Sneaky 'nanobeacon' delivers smackdown to cancer cells' defenses By silencing a mechanism that allows cancer cells to reject anti-cancer drugs, a new breakthrough out of MIT and Harvard could dramatically increase the efficacy of treatment.	Antibody-drug Gold Nanoantennas in GLOBAL MEDICAL DISCOVERY